OncoMatch/Clinical Trials/NCT06632262
A Phase 2 Clinical Study of ABSK061 and ABSK043
Is NCT06632262 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including ABSK061 + ABSK043 and ABSK061+ABSK043 in combination with CAPOX for her2-gastric/gastroesophageal junction cancer.
Treatment: ABSK061 + ABSK043 · ABSK061+ABSK043 in combination with CAPOX — The purpose of this study is to evaluate the anti-tumor activity of ABSK061 + ABSK043 in terms of overall response rate (ORR) in in Patients with Metastatic/Unresectable Solid Tumors with FGFR2/3 Alterations
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Esophageal Carcinoma
Urothelial Carcinoma
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Biomarker criteria
Required: FGFR2 activating mutation
FGFR2/3 activating mutations
Required: FGFR3 activating mutation
FGFR2/3 activating mutations
Required: FGFR2 fusion/rearrangement
FGFR2/3 fusions/rearrangements
Required: FGFR3 fusion/rearrangement
FGFR2/3 fusions/rearrangements
Required: FGFR2 amplification
FGFR2 amplification
Required: FGFR2 overexpression
FGFR2 overexpression
Required: FGFR3 overexpression
FGFR3 overexpression
Disease stage
Metastatic disease required
Performance status
WHO 0–1
Prior therapy
Cannot have received: FGFR pathway inhibitor
Previous treatment with an FGFR pathway inhibitor or a multi-kinase inhibitor designed to inhibit FGFR
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify